Combination Therapies against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirus disease 2019 (COVID-19), which was announced as a pandemic leading to devastating economic and medical burden worldwide. The virus attacks the organ system across the body by binding to its receptor (f...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2022-09-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/27/9/10.31083/j.fbl2709257 |
| _version_ | 1828131098567114752 |
|---|---|
| author | Qunfeng Luo Yunxi Zheng Jin Zhang |
| author_facet | Qunfeng Luo Yunxi Zheng Jin Zhang |
| author_sort | Qunfeng Luo |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirus disease 2019 (COVID-19), which was announced as a pandemic leading to devastating economic and medical burden worldwide. The virus attacks the organ system across the body by binding to its receptor (for example, angiotensin converting enzyme 2) on the surface of the host cell of various organs. The patients present with a variety of pathological symptoms ranging from fever, cough and cytokine storm to acute respiratory distress syndrome (ARDS). Many combination therapies have been developed to combat the disease, via blocking one or more processes of the viral life cycle and/or relieving host complications simultaneously. In this review, the progress of those combination therapies containing at least one small molecule is updated. We believe it’ll provide significant inspiration for further development of treatment strategy against SARS-CoV-2, especially its mutant variants. |
| first_indexed | 2024-04-11T16:42:23Z |
| format | Article |
| id | doaj.art-2803e6fc83104832ababb5b05cb7ee19 |
| institution | Directory Open Access Journal |
| issn | 2768-6701 |
| language | English |
| last_indexed | 2024-04-11T16:42:23Z |
| publishDate | 2022-09-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj.art-2803e6fc83104832ababb5b05cb7ee192022-12-22T04:13:38ZengIMR PressFrontiers in Bioscience-Landmark2768-67012022-09-0127925710.31083/j.fbl2709257S2768-6701(22)00606-2Combination Therapies against COVID-19Qunfeng Luo0Yunxi Zheng1Jin Zhang2School of Basic Medical Sciences, Nanchang University, 330047 Nanchang, Jiangxi, ChinaQueen Marry College, Nanchang University, 330047 Nanchang, Jiangxi, ChinaSchool of Basic Medical Sciences, Nanchang University, 330047 Nanchang, Jiangxi, ChinaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirus disease 2019 (COVID-19), which was announced as a pandemic leading to devastating economic and medical burden worldwide. The virus attacks the organ system across the body by binding to its receptor (for example, angiotensin converting enzyme 2) on the surface of the host cell of various organs. The patients present with a variety of pathological symptoms ranging from fever, cough and cytokine storm to acute respiratory distress syndrome (ARDS). Many combination therapies have been developed to combat the disease, via blocking one or more processes of the viral life cycle and/or relieving host complications simultaneously. In this review, the progress of those combination therapies containing at least one small molecule is updated. We believe it’ll provide significant inspiration for further development of treatment strategy against SARS-CoV-2, especially its mutant variants.https://www.imrpress.com/journal/FBL/27/9/10.31083/j.fbl2709257combination therapyanti-sars-cov-2complicationantiviralanti-inflammation |
| spellingShingle | Qunfeng Luo Yunxi Zheng Jin Zhang Combination Therapies against COVID-19 Frontiers in Bioscience-Landmark combination therapy anti-sars-cov-2 complication antiviral anti-inflammation |
| title | Combination Therapies against COVID-19 |
| title_full | Combination Therapies against COVID-19 |
| title_fullStr | Combination Therapies against COVID-19 |
| title_full_unstemmed | Combination Therapies against COVID-19 |
| title_short | Combination Therapies against COVID-19 |
| title_sort | combination therapies against covid 19 |
| topic | combination therapy anti-sars-cov-2 complication antiviral anti-inflammation |
| url | https://www.imrpress.com/journal/FBL/27/9/10.31083/j.fbl2709257 |
| work_keys_str_mv | AT qunfengluo combinationtherapiesagainstcovid19 AT yunxizheng combinationtherapiesagainstcovid19 AT jinzhang combinationtherapiesagainstcovid19 |